ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1085

Safety of Plasmapheresis as an Adjuvant Therapy in Severe Pediatric Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: A Single Center Cohort

Sharanya Joginpalli1, Alvaro Orjuela2, Marietta De Guzman3 and Emily Frierson2, 1Baylor College of Medicine- Texas Children's Hospital, Houston, TX, 2Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 3Baylor College of Medicine/ Texas Children's Hospital, Houston, TX

Meeting: ACR Convergence 2022

Keywords: ANCA, ANCA associated vasculitis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Therapeutic plasma exchange (TPE) is used in anti-neutrophil cytoplasmic antibody associated vasculitis (AAV) as adjunct treatment for severe disease. There is paucity of data as to the effectiveness and safety of TPE in children with ANCA associated vasculitis. There are different recommendations regarding the role of TPE in AAV and most studies are based on adult data. It is presumed that TPE procedure in pediatric patients can be technically challenging. The focus of this review is to study the safety of the TPE procedure when it is recommended for severe AAV with rapidly progressive glomerulonephritis (RPGN) and pulmonary hemorrhage patients in pediatric patients.

Methods: In this retrospective study, we reviewed a total of 93 TPE procedures that were performed on 18 patients during a 10-year period (2011-2021). 78% were females. 50% were Hispanic, 44% were Caucasian and 5% were African American.

Inpatient age ranged from 2 to 18 years with median age range of 13.1 years. Two patients at 2 years and 3 years of age with remaining patients between 9 and 18 years of age.

Indications for TPE were as follows: 5 patients with RPGN + diffuse alveolar hemorrhage (DAH), 11 patients with DAH, 1 patient with RPGN with no lung involvement and 1 patient was Antibody-mediated rejection (AMR) in transplant.

One patient received four TPE treatments in tandem to ECMO. 28% of total TPE procedures used only 25% albumin as replacement fluid.

88% of patients were critical in the ICU and remainder were on the pediatric floor. All patients received corticosteroids with additional immunomodulatory treatment including cyclophosphamide, rituximab, and IVIG.

Regarding adverse effects, hypocalcemia was defined by ionized calcium concentration below < 1 mm/L. Hypertension and hypotension criteria were defined by percentiles based on age of patient.

Results: Among a total of 88 TPE procedures, 16 adverse events were noted (18%). 11 episodes were allergic reactions manifested as hives without anaphylaxis, itching and mild SOB (12.5%). Two TPE procedures were stopped due progressive hives/itching. Hypotension (1) and hypertension (2) occurred. Two episodes of catheter access issues occurred, one of which led to discontinuation of TPE due to occlusive thrombus surrounding tip catheter. No episodes of symptomatic hypocalcemia or bleeding due to hypofibrinogenemia occurred.

Median eGFR (measured in mL/min/1.73m2) pre-TPE was 82.9, post-TPE was 81, at 1-month was 79.5 and at 3-months was 78. Out of 18 patients, one patient died. No TPE-associated mortality was noted.

Conclusion: Our cohort showed that TPE was a well-tolerated and safe adjunctive treatment for severe AAV in pediatric patients. Further study on a large-scale pediatric population is needed to better define its role and safety.


Disclosures: S. Joginpalli, None; A. Orjuela, None; M. De Guzman, None; E. Frierson, None.

To cite this abstract in AMA style:

Joginpalli S, Orjuela A, De Guzman M, Frierson E. Safety of Plasmapheresis as an Adjuvant Therapy in Severe Pediatric Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: A Single Center Cohort [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/safety-of-plasmapheresis-as-an-adjuvant-therapy-in-severe-pediatric-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-a-single-center-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-of-plasmapheresis-as-an-adjuvant-therapy-in-severe-pediatric-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-a-single-center-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology